Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Drug Imports Exceeds ¥1 Trillion, Trade Deficit at ¥700 Billion

This article was originally published in PharmAsia News

Executive Summary

Japan's trade data for 2007, released by the Department of Treasury, shows that the country's import of drugs increased by 8.8 percent to ¥1.078 trillion. EU was the biggest exporter, sending ¥634.4 billion worth of drugs to Japan and followed by the U.S., ¥168.3 billion. Import from China jumped 33.1 percent to ¥46.9 billion. Japan exported ¥374.4 billion worth of drugs in 2007, a 0.6 percent increase. The biggest importer of Japanese drugs was the U.S., with a total of ¥127 billion, and followed by EU, ¥119 billion. Japan's export to China was ¥22.7 billion. (Click here for more - Japanese language

You may also be interested in...

Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts